BR112022010165A2 - Agonistas de tlr7 - Google Patents

Agonistas de tlr7

Info

Publication number
BR112022010165A2
BR112022010165A2 BR112022010165A BR112022010165A BR112022010165A2 BR 112022010165 A2 BR112022010165 A2 BR 112022010165A2 BR 112022010165 A BR112022010165 A BR 112022010165A BR 112022010165 A BR112022010165 A BR 112022010165A BR 112022010165 A2 BR112022010165 A2 BR 112022010165A2
Authority
BR
Brazil
Prior art keywords
tlr7 agonists
tlr7
diseases
agonists
cancer
Prior art date
Application number
BR112022010165A
Other languages
English (en)
Inventor
E Webber Stephen
Richard Appleman James
Original Assignee
Primmune Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Primmune Therapeutics Inc filed Critical Primmune Therapeutics Inc
Publication of BR112022010165A2 publication Critical patent/BR112022010165A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

AGONISTAS DE TLR7. A presente invenção refere-se a agonistas de TLR7 de acordo com a Fórmula I e seu uso no tratamento de doenças como câncer e doenças infecciosas.
BR112022010165A 2019-11-26 2020-11-25 Agonistas de tlr7 BR112022010165A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962940622P 2019-11-26 2019-11-26
PCT/US2020/062344 WO2021108649A1 (en) 2019-11-26 2020-11-25 Tlr7 agonists

Publications (1)

Publication Number Publication Date
BR112022010165A2 true BR112022010165A2 (pt) 2022-08-09

Family

ID=75974715

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010165A BR112022010165A2 (pt) 2019-11-26 2020-11-25 Agonistas de tlr7

Country Status (17)

Country Link
US (2) US11692005B2 (pt)
EP (1) EP4065155A4 (pt)
JP (1) JP2023503996A (pt)
KR (1) KR20220150879A (pt)
CN (1) CN115427063A (pt)
AU (1) AU2020391487A1 (pt)
BR (1) BR112022010165A2 (pt)
CA (1) CA3163093A1 (pt)
CL (1) CL2022001377A1 (pt)
CO (1) CO2022008835A2 (pt)
CR (1) CR20220282A (pt)
EC (1) ECSP22049906A (pt)
IL (1) IL293293A (pt)
MX (1) MX2022006307A (pt)
PE (1) PE20221324A1 (pt)
TW (1) TW202134240A (pt)
WO (1) WO2021108649A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114917228B (zh) * 2022-06-07 2023-09-26 广西中医药大学 一种用于预防性治疗狂犬病的药方及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476659A (en) 1982-11-09 1995-12-19 The Scripps Research Institute Cancerous B cell treatment using substituted nucleoside derivatives
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
US5136030A (en) 1988-05-05 1992-08-04 Scripps Clinic And Research Foundation Immunostimulating guanine derivatives, compositions and methods
US5093319A (en) 1989-10-31 1992-03-03 Pfizer Hospital Products Group, Inc. Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions
AU5845594A (en) 1992-11-13 1994-06-08 Scripps Research Institute, The Cancerous b cell treatment using substituted nucleoside derivatives
KR100412480B1 (ko) 1996-10-16 2003-12-31 아이씨엔 파마슈티컬스, 인코포레이티드 푸린 ｌ-누클레오시드, 이의 유사체 및 이들의 용도
EP1232166A2 (en) 1999-11-12 2002-08-21 Pharmasset Limited Synthesis of 2'-deoxy-l-nucleosides
EP1296690A2 (en) 2000-02-18 2003-04-02 Shire Biochem Inc. METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES
CN101862345B (zh) 2000-10-18 2014-06-04 吉利德制药有限责任公司 用于治疗病毒感染和异常细胞增殖的修饰核苷类化合物
OA13310A (en) 2003-09-05 2007-04-13 Anadys Pharmaceuticals Inc TLR7 ligands for the treatment of hepatitis C.
ES2525567T3 (es) 2004-12-17 2014-12-26 Anadys Pharmaceuticals, Inc. Compuestos de 3H-oxazolo y 3H-tiazolo[4,5-d]pirimidin-2-ona 3,5-disustituidos y 3,5,7-trisustituidos y profármacos de los mismos
JP2010536787A (ja) 2007-08-15 2010-12-02 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｏｌｌ様受容体モジュレータ
DK2313111T3 (da) 2008-08-01 2013-12-02 Ventirx Pharmaceuticals Inc Toll-lignende receptoragonistformuleringer og anvendelse deraf
US20120095077A1 (en) 2009-03-23 2012-04-19 University Of Utah Research Foundation Methods and compositions related to modified guanine bases for controlling off-target effects in rna interference
EP2776070A4 (en) 2011-11-09 2016-02-10 Ascend Biopharmaceuticals Ltd IMMUNOMODULATORY CONJUGATES
WO2016004876A1 (en) 2014-07-09 2016-01-14 Shanghai Birdie Biotech, Inc. Anti-pd-l1 combinations for treating tumors
CA2963717C (en) 2014-12-08 2023-10-10 F. Hoffmann-La Roche Ag 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
CN107427514B (zh) 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
CN106943596A (zh) 2016-01-07 2017-07-14 博笛生物科技（北京）有限公司 用于治疗肿瘤的抗-cd20组合
CN110177791B (zh) 2016-12-20 2022-07-12 阿斯利康(瑞典)有限公司 氨基-三唑并吡啶化合物及其在治疗癌症中的用途
EP3801538A4 (en) 2018-05-25 2022-03-09 Primmune Therapeutics, Inc. TLR7 AGONISTS

Also Published As

Publication number Publication date
ECSP22049906A (es) 2022-07-29
US20240116974A1 (en) 2024-04-11
EP4065155A1 (en) 2022-10-05
US20210155652A1 (en) 2021-05-27
KR20220150879A (ko) 2022-11-11
US11692005B2 (en) 2023-07-04
PE20221324A1 (es) 2022-09-09
AU2020391487A1 (en) 2022-07-07
MX2022006307A (es) 2022-08-22
EP4065155A4 (en) 2023-11-29
WO2021108649A1 (en) 2021-06-03
CN115427063A (zh) 2022-12-02
IL293293A (en) 2022-07-01
JP2023503996A (ja) 2023-02-01
CA3163093A1 (en) 2021-06-03
CR20220282A (es) 2022-11-28
CL2022001377A1 (es) 2023-04-10
CO2022008835A2 (es) 2022-07-19
TW202134240A (zh) 2021-09-16

Similar Documents

Publication Publication Date Title
CL2020000501A1 (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos.
CO2018010966A2 (es) Nuevos derivados de pirazolopirimidina
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
ECSP20082988A (es) Agonistas de tlr7
ECSP19057713A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas para el tratamiento del cáncer
CL2021000088A1 (es) Anticuerpos anti-cd27 (divisional de solicitud 779-2019).
EA202090258A3 (ru) Производные пирроло[3,2-d]пиримидина для лечения вирусных инфекций и других заболеваний
CO6960552A2 (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
BR112015029386A2 (pt) uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer
BR112018000254A2 (pt) inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
PH12020550583A1 (en) Use of riluzole prodrugs to treat ataxias
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
BR112022010165A2 (pt) Agonistas de tlr7
CL2018002368A1 (es) Formulaciones de oritavancina
CL2020000127A1 (es) Moduladores terapéuticos del modo inverso de la atp sintasa.
BR112019007631A2 (pt) inibidores de bromodomínios
BR112022004777A2 (pt) Composição de micela de estimulação imunológica
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CR20150641U (es) Composiciones farmacéuticas
AR111715A1 (es) ANTICUERPOS ANTI-SIRPa
BR112014026158A2 (pt) métodos e composições para o tratamento de infecções virais
BR112021019589A2 (pt) Derivados de isocromenos como inibidores de fosfoinositídeo 3-cinases
MX2020004871A (es) Derivados de acido cafeico y sus usos.
BR102017018497A8 (pt) picolinamidas como fungicidas